BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries

[1]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[2]  G. A. Marcoulides,et al.  Full Information Estimation in the Presence of Incomplete Data , 2013 .

[3]  L. Kappelle,et al.  Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. , 2013, International journal of cardiology.

[4]  G. Pasterkamp,et al.  Plasma extracellular vesicle protein content for diagnosis and prognosis of global cardiovascular disease , 2013, Netherlands Heart Journal.

[5]  P. Douglas,et al.  A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study , 2013, Circulation. Cardiovascular genetics.

[6]  S. Blankenberg,et al.  Blood-based gene expression tests: promises and limitations. , 2013, Circulation. Cardiovascular genetics.

[7]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  D. Owens,et al.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  William E. Kraus,et al.  Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular Diseases: Form and Function , 2012, Circulation.

[10]  Thomas P Cappola,et al.  Transcriptomic biomarkers of cardiovascular disease. , 2012, Progress in cardiovascular diseases.

[11]  M. Niemelä,et al.  Description of MORGAM Cohorts , 2012 .

[12]  R. Gerszten,et al.  Metabolomics and cardiovascular biomarker discovery. , 2012, Clinical chemistry.

[13]  Stefanie Dimmeler,et al.  Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Steven A Carr,et al.  Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. , 2011, Circulation research.

[15]  C. Herder,et al.  Biomarkers for the Prediction of Type 2 Diabetes and Cardiovascular Disease , 2011, Clinical pharmacology and therapeutics.

[16]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[17]  E. Rooij,et al.  The Art of MicroRNA Research , 2011 .

[18]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[19]  J. Cohn,et al.  Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010, Circulation.

[20]  E. Benjamin,et al.  Multiple marker approach to risk stratification in patients with stable coronary artery disease. , 2010, European heart journal.

[21]  Olli Saarela,et al.  Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project , 2010, Circulation.

[22]  Silke Szymczak,et al.  Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility , 2010, PloS one.

[23]  V. Salomaa,et al.  Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes , 2010, PloS one.

[24]  Geoffrey S Ginsburg,et al.  Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events , 2010, Circulation. Cardiovascular genetics.

[25]  Michael Marber,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction , 2010 .

[26]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[27]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[28]  J. Sundström,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .

[29]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[30]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[31]  Olli Saarela,et al.  Epidemiologic Perspectives & Innovations Open Access Case-cohort Design in Practice – Experiences from the Morgam Project , 2007 .

[32]  P. Bühlmann,et al.  Survival ensembles. , 2006, Biostatistics.

[33]  Sangita Kulathinal,et al.  MORGAM (an international pooling of cardiovascular cohorts). , 2004, International journal of epidemiology.

[34]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[35]  H. Tunstall-Pedoe,et al.  MONICA Monograph and Multimedia Sourcebook , 2003 .

[36]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[37]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[38]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[39]  G. A. Marcoulides,et al.  Advanced structural equation modeling : issues and techniques , 1996 .

[40]  James L. Arbuckle,et al.  Full Information Estimation in the Presence of Incomplete Data , 1996 .

[41]  F. Henry,et al.  Cost effectiveness. , 1980, The Ohio State medical journal.

[42]  C. Dolea,et al.  World Health Organization , 1949, International Organization.